Pan-cancer prognostic genetic mutations and clinicopathological factors associated with survival outcomes: a systematic review

被引:0
作者
Jurgita Gammall
Alvina G. Lai
机构
[1] Institute of Health Informatics,
[2] University College London,undefined
[3] Cerner Limited,undefined
[4] Health Data Research UK,undefined
来源
npj Precision Oncology | / 6卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Cancer is a leading cause of death, accounting for almost 10 million deaths annually worldwide. Personalised therapies harnessing genetic and clinical information may improve survival outcomes and reduce the side effects of treatments. The aim of this study is to appraise published evidence on clinicopathological factors and genetic mutations (single nucleotide polymorphisms [SNPs]) associated with prognosis across 11 cancer types: lung, colorectal, breast, prostate, melanoma, renal, glioma, bladder, leukaemia, endometrial, ovarian. A systematic literature search of PubMed/MEDLINE and Europe PMC was conducted from database inception to July 1, 2021. 2497 publications from PubMed/MEDLINE and 288 preprints from Europe PMC were included. Subsequent reference and citation search was conducted and a further 39 articles added. 2824 articles were reviewed by title/abstract and 247 articles were selected for systematic review. Majority of the articles were retrospective cohort studies focusing on one cancer type, 8 articles were on pan-cancer level and 6 articles were reviews. Studies analysing clinicopathological factors included 908,567 patients and identified 238 factors, including age, gender, stage, grade, size, site, subtype, invasion, lymph nodes. Genetic studies included 210,802 patients and identified 440 gene mutations associated with cancer survival, including genes TP53, BRCA1, BRCA2, BRAF, KRAS, BIRC5. We generated a comprehensive knowledge base of biomarkers that can be used to tailor treatment according to patients’ unique genetic and clinical characteristics. Our pan-cancer investigation uncovers the biomarker landscape and their combined influence that may help guide health practitioners and researchers across the continuum of cancer care from drug development to long-term survivorship.
引用
收藏
相关论文
共 32 条
[1]  
Sung H(2021)Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J. Clin. 71 209-249
[2]  
Alexander M(2017)Lung cancer prognostic index: A risk score to predict overall survival after the diagnosis of non-small-cell lung cancer Br. J. Cancer 117 744-751
[3]  
Dienstmann R(2017)Prediction of overall survival in stage II and III colon cancer beyond TNM system: A retrospective, pooled biomarker study Ann. Oncol. 28 1023-1031
[4]  
Vargas AJ(2016)Biomarker development in the precision medicine era: Lung cancer as a case study Nat. Rev. Cancer 16 525-537
[5]  
Harris CC(2017)Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13 BMJ 2017 359 j4530-182
[6]  
Davis C(2010)TP53 mutations in human cancers: origins, consequences, and clinical use Cold Spring Harb. Perspect. Biol. 2 a001008-4689
[7]  
Olivier M(2015)PTEN: multiple functions in human malignant tumors Front Oncol. 5 24-862
[8]  
Hollstein M(2002)Cancer susceptibility and the functions of BRCA1 and BRCA2 Cell 108 171-312
[9]  
Hainaut P(1989)ras oncogenes in human cancer: Areview [published correction appears in Cancer Res 1990 Feb 15;50(4):1352] Cancer Res. 49 4682-489
[10]  
Milella M(2011)BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer Br. J. Cancer 104 856-1011